Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission
Gabriel N. Mannis(Stanford University), Charalambos Andreadis(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Lloyd E. Damon(University of California, San Francisco), Rebecca L. Olin(University of California, San Francisco), Aaron C. Logan(University of California, San Francisco), Michael Flanders(Harvard University), Catherine C. Smith(University of California, San Francisco), Karin Gaensler(University of California, San Francisco), Jeffrey L. Wolf(City College of San Francisco), Thomas G. Martin(University of Colorado Boulder), Peter H. Sayre(Immune Tolerance Network)
Cited by 11
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782